ArticleViruses2022
The Role of Bacterial and Fungal Superinfection in Critical COVID-19.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Incidence, mortality and risk factors of invasive pulmonary aspergillosis in critically ill patients during the COVID-19 era: a global systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2026Pooled it
- Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Predictive nomogram for early detection of invasive fungal disease deterioration --- a 10-year retrospective cohort study.BMC infectious diseases · 2025Article
- Impact of mechanical ventilation on severe acute kidney injury in critically ill patients with and without COVID-19 - a multicentre propensity matched analysis.Annals of intensive care · 2025Article
- Major alteration of lung microbiome and the host responses in critically ill COVID-19 patients with high viral load.Scientific reports · 2024Article
- Non-Conventional Prognostic Markers in Life-Threatening COVID-19 Cases-When Less Is More.Journal of clinical medicine · 2024Article
- Major alteration of Lung Microbiome and the Host Reaction in critically ill COVID-19 Patients with high viral load.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe range of reported rates of bacterial and fungal superinfections in patients with a severe course of COVID-19 is wide, suggesting a lack of standardised reporting.
methodsThe rates of bacterial and fungal superinfection were assessed using predefined criteria to differentiate between infection and contamination.
resultsOverall, 117 patients admitted to the Intensive Care Unit due to severe COVID-19 were included. Overall, 55% of patients developed a superinfection and 13.6% developed a fungal superinfection (5.9% candidemia and 7.7% CAPA). The rate of ventilator-associated pneumonia was 65.2%. If superinfection was detected, the length of hospital stay was significantly longer and the mortality was especially increased if candidemia was detected. An increased risk of superinfection was observed in patients with pre-existing diabetes mellitus or chronic heart failure. The presence of immunomodulating therapy did not seem to have an impact on the frequency of superinfections.
conclusionIncreased awareness of high superinfection rates, fungal infections in particular, in patients suffering from severe COVID-19 is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.